Major Depressive Disorder Market Report and Forecast 2024-2032

Major Depressive Disorder Market Report and Forecast 2024-2032


Major Depressive Disorder Market Report and Forecast 2024-2032

The major depressive disorder market size was valued at USD 6.1 billion in 2023, driven by the increasing stress levels in modern lifestyles and awareness across the 8 major markets. The market is expected to grow at a CAGR of 5.3% during the forecast period of 2024-2032, with the value likely to reach USD 9.6 billion by 2032.

Major Depressive Disorder Market Analysis

The major depressive disorder (MDD) market analysis reveals a complex landscape shaped by increasing global prevalence, evolving treatment paradigms, and significant investment in mental health research and development. This comprehensive analysis covers the current state of the MDD market, including trends, challenges, and future outlooks.

The MDD market has been experiencing robust growth, driven by a rising awareness of mental health issues and the destigmatization of seeking treatment. The global prevalence of MDD has seen a steady increase, attributed to various factors including socioeconomic pressures, lifestyle changes, and the impact of global events such as the COVID-19 pandemic, which has intensified focus on mental health services and support systems.

Market Challenges
  • Treatment-Resistant Depression: A significant portion of the MDD population is treatment-resistant, highlighting the need for ongoing research into more effective treatment strategies and the importance of personalized treatment plans.
  • Access to Care: Despite increased awareness, access to mental health services remains a challenge in many regions, impacted by factors such as healthcare infrastructure, socioeconomic status, and stigma.
  • The future of the MDD market is poised for significant advancements, with several key areas identified for growth and development:
  • Next-Generation Antidepressants: Research and development efforts are focused on next-generation drugs that offer faster onset of action, improved efficacy, and fewer side effects.
  • Expansion of Digital and Telehealth Services: The expansion of digital health solutions and telehealth is expected to continue, breaking down barriers to access and offering personalized treatment options.
  • Holistic and Preventative Approaches: There's an increasing focus on preventative measures and holistic approaches to mental health, emphasizing early intervention, lifestyle modifications, and the social determinants of mental health.
Major Depressive Disorder Market Trends

The market for treatments and solutions addressing major depressive disorder (MDD) has witnessed significant trends and developments over recent years, reflecting a dynamic interplay of clinical needs, technological advancements, and evolving healthcare practices. These trends not only highlight the growing awareness and understanding of MDD but also underscore the challenges and opportunities within the market. Here are key trends shaping the MDD market:

1.Increased Prevalence and Awareness

There has been a noticeable increase in the prevalence of MDD globally, attributed to factors such as heightened stress levels in modern lifestyles, greater awareness, and improved diagnostic practices. This rise in diagnosed cases has spurred demand for effective treatment solutions, driving market growth.

2. Shift Towards Personalized Medicine

The trend towards personalized or precision medicine is becoming prominent in the MDD market. There's a growing emphasis on tailoring treatment approaches to individual patient profiles, considering genetic, environmental, and personal health factors. This approach aims to enhance treatment efficacy and reduce side effects, leading to better patient outcomes.

3. Advancements in Pharmacotherapy

Innovations in pharmacotherapy, including the development of new drug classes such as ketamine-based therapies, offer novel mechanisms of action compared to traditional antidepressants. These new treatments, promising faster onset of effects and efficacy in treatment-resistant cases, are reshaping treatment paradigms.

4. Digital Therapeutics and mHealth

The integration of digital therapeutics and mobile health (mHealth) applications into treatment strategies is a growing trend. These technologies offer innovative ways to manage and treat MDD, including remote monitoring, digital counseling, and therapeutic games, enhancing accessibility and patient engagement.

5. Focus on Comprehensive Care Models

There's a shifting focus towards comprehensive care models that integrate pharmacological treatments with psychotherapy, lifestyle changes, and support systems. This holistic approach addresses the multifaceted nature of MDD, aiming for not just symptom management but overall well-being.

6. Regulatory and Reimbursement Landscape

Changes in regulatory guidelines and reimbursement policies for MDD treatments are influencing market dynamics. There's an increasing recognition of the need for broader access to advanced treatments, including psychotherapies and novel pharmacotherapies, which is prompting changes in healthcare policies.

7. Investment in Research and Development

The MDD market is characterized by robust investment in research and development, driven by the urgent need for more effective and faster-acting treatments. This includes exploring the therapeutic potential of psychedelics, neurostimulation technologies, and investigating the underlying biological pathways of MDD.

Major Depressive Disorder Market Segmentation

Market Breakup by Product Type
  • Benzodiazepines
  • Antidepressant Drugs
  • SSRIs
  • SNRIs
  • Others
The major depressive disorder (MDD) market, segmented by product type into benzodiazepines, antidepressant drugs, SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), and others, is positioned for significant growth, driven by a combination of increasing global awareness of mental health issues and advancements in pharmacological treatments. Antidepressant drugs, particularly SSRIs and SNRIs, have emerged as front-line therapies due to their efficacy in managing symptoms and relatively favorable side effect profiles, positioning them as key drivers of market expansion. The development of novel antidepressants and the growing acceptance of mental health treatments are further propelling the demand for these medications.

Benzodiazepines, although effective for short-term relief of MDD symptoms, face limitations due to their potential for dependence and side effects, leading to more cautious prescribing practices. The "others" category, including novel drug classes and combination therapies, reflects the market's move towards personalized medicine, aiming to address the diverse needs and biological responses of patients. As research continues to uncover the complex pathophysiology of MDD, the market is set to evolve with more targeted and effective treatments, driving growth in the forecast period. This evolution underscores the pharmaceutical industry's focus on innovation and the global shift towards prioritizing mental health care.

Market Breakup by Treatment Type
  • Medication
  • Antidepressant Drugs
  • Adjunctive Therapies
  • Psychotherapy
  • Cognitive Behavioral Therapy (CBT)
  • Interpersonal Therapy (IPT)
  • Other Therapeutic Approaches
  • Brain Stimulation Therapies
  • Electroconvulsive Therapy (ECT)
  • Transcranial Magnetic Stimulation (TMS)
The major depressive disorder (MDD) market, segmented by treatment type into medication, antidepressant drugs, adjunctive therapies, psychotherapy, cognitive behavioral therapy (CBT), interpersonal therapy (IPT), other therapeutic approaches, and brain stimulation therapies such as electroconvulsive therapy (ECT), presents a multifaceted landscape poised for growth. Medications, particularly antidepressant drugs, remain the cornerstone of MDD treatment, offering a broad range of options to tailor treatment plans to individual patient needs. The role of adjunctive therapies, including the use of antipsychotics or mood stabilizers in conjunction with antidepressants, highlights the market's move towards comprehensive treatment regimens.

Psychotherapy, with modalities like CBT and IPT, underscores the increasing recognition of the importance of addressing the psychological aspects of MDD, offering growth opportunities for services beyond pharmacotherapy. These therapies have gained traction for their effectiveness in improving outcomes, especially when used alongside medication.

Other therapeutic approaches and innovations in brain stimulation therapies, such as ECT and emerging modalities like transcranial magnetic stimulation (TMS), reflect the ongoing search for effective treatments for drug-resistant depression, driving market expansion. As the understanding of MDD deepens, the demand for diverse and complementary treatment options is expected to rise, contributing to market growth. This trend is fueled by growing awareness of mental health, the destigmatization of mental illness, and an increasing emphasis on personalized treatment plans, setting the stage for the market's continued evolution in addressing the complex needs of MDD patients.

Market Breakup by Diagnosis Tests
  • Psychological Assessments
  • Blood Tests
  • Imaging Technologies
  • Laboratory Tests
  • Other Diagnostic Tools
The major depressive disorder (MDD) market, segmented by diagnosis tests into psychological assessments, blood tests, imaging technologies, laboratory tests, and other diagnostic tools, is a critical area reflecting the complexity and multifaceted nature of diagnosing MDD. Psychological assessments remain the cornerstone of MDD diagnosis, utilizing standardized questionnaires and interviews to evaluate symptom severity and the impact on daily functioning. These assessments are pivotal for accurate diagnosis and tailoring treatment plans to individual patient needs, driving demand for skilled clinical evaluation.

Blood tests and laboratory tests, while not used to diagnose MDD directly, are increasingly important for ruling out physical conditions that may mimic or contribute to depressive symptoms, such as thyroid disorders or vitamin deficiencies. This comprehensive approach ensures a more accurate diagnosis and appropriate treatment strategy.

Imaging technologies, although not routinely used for MDD diagnosis, offer potential growth areas in understanding the disease's neurobiological underpinnings. Advances in MRI and PET scans can provide insights into brain activity patterns associated with depression, supporting ongoing research into more targeted treatments.

Other diagnostic tools, including digital health platforms and wearable technology, are emerging as significant segments. These tools can monitor patient symptoms in real-time, offering innovative ways to support diagnosis and treatment monitoring. As the understanding of MDD evolves, these diagnostic segments are poised to drive market growth, supported by advancements in technology and an integrated approach to mental health care.

Market Breakup by Distribution Channel
  • Pharmacies and Retail Stores
  • Online Pharmacies
  • Hospitals and Clinics
  • Others
The major depressive disorder (MDD) market, segmented by distribution channel into pharmacies and retail stores, online pharmacies, hospitals and clinics, and others, showcases the diverse pathways through which treatments and services reach patients. Pharmacies and retail stores are traditional, essential access points for medication and over-the-counter (OTC) treatments, playing a crucial role in the availability of antidepressants and adjunctive therapies. The convenience and widespread presence of these outlets support their continued dominance in the distribution landscape.

Online pharmacies have emerged as a significant segment, offering patients convenience, privacy, and often competitive pricing for medications. This channel has seen substantial growth, driven by the increasing digitization of healthcare and consumer preferences for online shopping, expanding access to MDD treatments.

Hospitals and clinics represent a vital distribution channel, particularly for more intensive treatments such as psychotherapy, cognitive behavioral therapy (CBT), and brain stimulation therapies like electroconvulsive therapy (ECT). These settings are crucial for providing comprehensive care, from diagnosis to treatment, especially for severe or complex cases of MDD.

Market Breakup by End User
  • Hospitals and Clinics
  • Mental Health Centres
  • Ambulatory Surgical Centres (ASCs)
The major depressive disorder (MDD) market, categorized by end user into hospitals and clinics, mental health centers, and ambulatory surgical centers (ASCs), delineates the primary care settings for patients suffering from MDD. Hospitals and clinics are central to the delivery of comprehensive care, offering a range of services from diagnosis to treatment, including medication management, psychotherapy, and, in some cases, inpatient care for severe episodes. Their role is pivotal in managing acute phases of MDD and providing integrated care plans.

Mental health centers specialize in psychiatric and psychological services, focusing on outpatient treatment modalities such as cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). These centers play a crucial role in ongoing management and support for individuals with MDD, emphasizing the importance of specialized care tailored to mental health needs.

Ambulatory Surgical Centers (ASCs), while traditionally focused on surgical care, have begun to offer certain outpatient mental health services, including innovative treatments like electroconvulsive therapy (ECT) for treatment-resistant depression. The inclusion of ASCs reflects the evolving landscape of treatment options available for MDD and the market's adaptation to cater to diverse patient needs and preferences.

Collectively, these end users form a comprehensive network for addressing MDD, from initial diagnosis to advanced treatment strategies. The segmentation by end user highlights the multidimensional approach required to effectively manage MDD, underlining the importance of specialized care facilities in enhancing patient outcomes and driving market growth in the forecast period.

Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • China
The major depressive disorder (MDD) market, segmented by region, showcases distinct characteristics and growth dynamics across key areas: the United States, EU-4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.

The United States leads in the MDD market, attributed to its advanced healthcare infrastructure, high awareness of mental health issues, and substantial investment in healthcare services, including mental health. The robust presence of healthcare providers and a strong focus on research and development contribute to the country's leading position.

In Europe, the EU-4 and the United Kingdom collectively represent a significant market for MDD treatments. Each country exhibits a strong healthcare system with an emphasis on mental health services, supported by government initiatives and policies aimed at improving mental health care access and quality. The diversity in healthcare systems and policies across these regions contributes to varied market dynamics.

Japan's MDD market is influenced by its aging population and increasing recognition of mental health issues. The country has made strides in addressing the stigma associated with mental health, leading to greater demand for treatment services and support.

China's market is rapidly growing, driven by economic development, increasing awareness of mental health, and improvements in healthcare infrastructure. The expanding middle class and government initiatives to enhance mental health services are key factors propelling market growth in the region.

Major Depressive Disorder Market Competitive Landscape

The competitive landscape of the major depressive disorder (MDD) market features a dynamic mix of pharmaceutical giants and emerging biotech firms, each contributing to the advancement of treatment options. Key players involved in the market are Lundbeck, AbbVie, Relmada Therapeutics, Axsome Therapeutics, Alkermes, Intra-Cellular Therapies, Allergan plc, Pfizer Inc., Sanofi S.A., Johnson & Johnson, Merck & Co., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AstraZeneca Plc, and GSK plc. Together, these companies drive innovation, enhance patient outcomes, and shape the competitive dynamics of the MDD market through their research efforts and development of new therapeutic options.

Key Questions Answered in This Report
  • What is the past and future performance of the major depressive disorder market?
  • What are the current challenges and future directions for growth and improvement in the major depressive disorder (MDD) market?
  • How does each driver, restraint, and opportunity affect the market?
  • What are the 8 regional markets?
  • Which countries have the most potential in the market?
  • What are the key market trends shaping the major depressive disorder (MDD) treatment landscape in recent years?
  • What are the key distribution channels for major depressive disorder treatments and how do they impact patient access?
  • How is the market segmented based on the diagnosis tests?
  • What is the market structure in terms of competition?
  • What are the main players/companies in the market?
Key Benefits for Stakeholders
  • The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the major depressive disorder market from 2017-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the major depressive disorder market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the major depressive disorder market industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Major Depressive Disorder Market Overview – 8 Major Markets
3.1 Major Depressive Disorder Market Historical Value (2017-2023)
3.2 Major Depressive Disorder Market Forecast Value (2024-2032)
4 Major Depressive Disorder Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Therapy Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Therapy Success Rate
6 Major Depressive Disorder Epidemiology Analysis- 8 Major Markets
6.1 8 MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.1 Germany Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.2 France Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.3 Italy Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.4 Spain Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.4 Japan Major Depressive Disorder Epidemiology Forecast (2017-2032)
6.5 China Major Depressive Disorder Epidemiology Forecast (2017-2032)
7 Major Depressive Disorder Market Landscape*- 8 Major Markets
7.1 Major Depressive Disorder Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Major Depressive Disorder Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Treatment Type
8 Major Depressive Disorder Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Major Depressive Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Porter’s Five Forces Model
10.5 Key Demand Indicators
10.6 Key Price Indicators
10.7 Industry Events, Initiatives, and Trends
10.8 Value Chain Analysis
11 Major Depressive Disorder Market Segmentation (2017-2032) - 8 Major Markets
11.1 Major Depressive Disorder Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Benzodiazepines
11.1.3 Antidepressant Drugs
11.1.4 SSRIs
11.1.5 SNRIs
11.1.6 Others
11.2 Major Depressive Disorder Market (2017-2032) by Treatment Type
11.2.1 Market Overview
11.2.2 Medication
11.2.2.1 Antidepressant Drugs
11.2.2.2 Adjunctive Therapies
11.2.3 Psychotherapy
11.2.3.1 Cognitive Behavioral Therapy (CBT)
11.2.3.2 Interpersonal Therapy (IPT)
11.2.3.3 Other Therapeutic Approaches
11.2.4 Brain Stimulation Therapies
11.2.4.1 Electroconvulsive Therapy (ECT)
11.2.4.2 Transcranial Magnetic Stimulation (TMS)
11.3 Major Depressive Disorder Market (2017-2032) by Diagnosis Tests
11.3.1 Market Overview
11.3.2 Psychological Assessments
11.3.3 Blood Tests
11.3.4 Imaging Technologies
11.3.5 Laboratory Tests
11.3.6 Other Diagnostic Tools
11.4 Major Depressive Disorder Market (2017-2032) by Distribution Channel
11.4.1 Market Overview
11.4.2 Pharmacies and Retail Stores
11.4.3 Online Pharmacies
11.4.4 Hospitals and Clinics
11.4.5 Others
11.5 Major Depressive Disorder Market (2017-2032) by End User
11.5.1 Market Overview
11.5.2 Hospitals and Clinics
11.5.3 Mental Health Centres
11.5.4 Ambulatory Surgical Centres (ASCs)
11.6 Major Depressive Disorder Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 China
12 United States Major Depressive Disorder Market (2017-2032)
12.1 United States Major Depressive Disorder Market Historical Value (2017-2023)
12.2 United States Major Depressive Disorder Market Forecast Value (2024-2032)
12.3 United States Major Depressive Disorder Market (2017-2032) by Product Type
12.3.1 Market Overview
12.3.2 Benzodiazepines
12.3.3 Antidepressant Drugs
12.3.4 SSRIs
12.3.5 SNRIs
12.3.6 Others
12.4 Major Depressive Disorder Market (2017-2032) by Treatment Type
12.4.1 Market Overview
12.4.2 Medication
12.4.2.1 Antidepressant Drugs
12.4.2.2 Adjunctive Therapies
12.4.3 Psychotherapy
12.4.3.1 Cognitive Behavioral Therapy (CBT)
12.4.3.2 Interpersonal Therapy (IPT)
12.4.3.3 Other Therapeutic Approaches
12.4.4 Brain Stimulation Therapies
12.4.4.1 Electroconvulsive Therapy (ECT)
12.4.4.2 Transcranial Magnetic Stimulation (TMS)
13 EU-4 and United Kingdom Major Depressive Disorder Market (2017-2032)
13.1 EU-4 and United Kingdom Major Depressive Disorder Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Major Depressive Disorder Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Major Depressive Disorder Market (2017-2032) by Product Type
13.3.1 Market Overview
13.3.2 Benzodiazepines
13.3.3 Antidepressant Drugs
13.3.4 SSRIs
13.3.5 SNRIs
13.3.6 Others
13.4 EU-4 and United Kingdom Major Depressive Disorder Market (2017-2032) by Treatment Type
13.4.1 Market Overview
13.4.2 Medication
13.4.2.1 Antidepressant Drugs
13.4.2.2 Adjunctive Therapies
13.4.3 Psychotherapy
13.4.3.1 Cognitive Behavioral Therapy (CBT)
13.4.3.2 Interpersonal Therapy (IPT)
13.4.3.3 Other Therapeutic Approaches
13.4.4 Brain Stimulation Therapies
13.4.4.1 Electroconvulsive Therapy (ECT)
13.4.4.2 Transcranial Magnetic Stimulation (TMS)
14 Japan Major Depressive Disorder Market (2017-2032)
14.1 Japan Major Depressive Disorder Market Historical Value (2017-2023)
14.2 Japan Major Depressive Disorder Market Forecast Value (2024-2032)
14.3 Japan Major Depressive Disorder Market (2017-2032) by Product Type
14.3.1 Market Overview
14.3.2 Benzodiazepines
14.3.3 Antidepressant Drugs
14.3.4 SSRIs
14.3.5 SNRIs
14.3.6 Others
14.4 Japan Major Depressive Disorder Market (2017-2032) by Treatment Type
14.4.1 Market Overview
14.4.2 Medication
14.4.2.1 Antidepressant Drugs
14.4.2.2 Adjunctive Therapies
14.4.3 Psychotherapy
14.4.3.1 Cognitive Behavioral Therapy (CBT)
14.4.3.2 Interpersonal Therapy (IPT)
14.4.3.3 Other Therapeutic Approaches
14.4.4 Brain Stimulation Therapies
14.4.4.1 Electroconvulsive Therapy (ECT)
14.4.4.2 Transcranial Magnetic Stimulation (TMS)
15 China Major Depressive Disorder Market (2017-2032)
15.1 China Major Depressive Disorder Market Historical Value (2017-2023)
15.2 China Major Depressive Disorder Market Forecast Value (2024-2032)
15.3 China Major Depressive Disorder Market (2017-2032) by Product Type
15.3.1 Market Overview
15.3.2 Benzodiazepines
15.3.3 Antidepressant Drugs
15.3.4 SSRIs
15.3.5 SNRIs
15.3.6 Others
15.4 China Major Depressive Disorder Market (2017-2032) by Treatment Type
15.4.1 Market Overview
15.4.2 Medication
15.4.2.1 Antidepressant Drugs
15.4.2.2 Adjunctive Therapies
15.4.3 Psychotherapy
15.4.3.1 Cognitive Behavioral Therapy (CBT)
15.4.3.2 Interpersonal Therapy (IPT)
15.4.3.3 Other Therapeutic Approaches
15.4.4 Brain Stimulation Therapies
15.4.4.1 Electroconvulsive Therapy (ECT)
15.4.4.2 Transcranial Magnetic Stimulation (TMS)
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 JAPAN PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Lundbeck
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 AbbVie
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Relmada Therapeutics
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Axsome Therapeutics
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Alkermes
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Intra-Cellular Therapies
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Allergan plc
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Pfizer Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Sanofi S.A.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Johnson & Johnson
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Merck & Co.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Eli Lilly and Company
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Takeda Pharmaceutical Company Limited
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 AstraZeneca Plc
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 GSK plc
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
23 Major Depressive Disorder Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings